MY188089A - Prodrugs for the treatment of cancer - Google Patents

Prodrugs for the treatment of cancer

Info

Publication number
MY188089A
MY188089A MYPI2017700615A MYPI2017700615A MY188089A MY 188089 A MY188089 A MY 188089A MY PI2017700615 A MYPI2017700615 A MY PI2017700615A MY PI2017700615 A MYPI2017700615 A MY PI2017700615A MY 188089 A MY188089 A MY 188089A
Authority
MY
Malaysia
Prior art keywords
cancer
treatment
prodrugs
c6alkyl
indolyl
Prior art date
Application number
MYPI2017700615A
Other languages
English (en)
Inventor
Richard Bethel
Anders Eneroth
Bjorn Klasson
Fredrik Oberg
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of MY188089A publication Critical patent/MY188089A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI2017700615A 2014-08-25 2015-08-24 Prodrugs for the treatment of cancer MY188089A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1450983 2014-08-25
SE1550858 2015-06-22
PCT/EP2015/069370 WO2016030335A1 (en) 2014-08-25 2015-08-24 Dioxolane analogues of uridine for the treatment of cancer

Publications (1)

Publication Number Publication Date
MY188089A true MY188089A (en) 2021-11-17

Family

ID=54014804

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI2017700615A MY188089A (en) 2014-08-25 2015-08-24 Prodrugs for the treatment of cancer
MYPI2021007010A MY198325A (en) 2014-08-25 2017-02-22 Prodrugs for the Treatment of Cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
MYPI2021007010A MY198325A (en) 2014-08-25 2017-02-22 Prodrugs for the Treatment of Cancer

Country Status (24)

Country Link
US (7) US10144750B2 (enExample)
EP (2) EP3186244B1 (enExample)
JP (2) JP6663424B2 (enExample)
KR (2) KR102398714B1 (enExample)
CN (4) CN111269264A (enExample)
AU (2) AU2015308988C1 (enExample)
BR (1) BR112017003898B1 (enExample)
CA (2) CA2956251C (enExample)
CY (1) CY1122945T1 (enExample)
DK (2) DK3572410T3 (enExample)
EA (2) EA033300B1 (enExample)
ES (2) ES2796089T3 (enExample)
HR (1) HRP20201023T1 (enExample)
HU (2) HUE050705T2 (enExample)
IL (2) IL250344B (enExample)
MX (1) MX369649B (enExample)
MY (2) MY188089A (enExample)
NZ (2) NZ729118A (enExample)
PH (2) PH12017500184A1 (enExample)
PL (2) PL3572410T3 (enExample)
PT (2) PT3186244T (enExample)
SG (3) SG10202001117YA (enExample)
WO (1) WO2016030335A1 (enExample)
ZA (1) ZA201802864B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102398714B1 (ko) * 2014-08-25 2022-05-17 메디비르 아베 암 치료를 위한 우리딘의 디옥솔란 유사체
CN106543220A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
RS62593B1 (sr) 2015-12-11 2021-12-31 NuCana plc Dijastereoselektivna sinteza derivata fosfata i proleka gemcitabina nuc-1031
CA3014769C (en) * 2016-03-02 2024-01-09 Medivir Aktiebolag Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
CN106432328B (zh) * 2016-09-14 2019-03-22 江苏福瑞生物医药有限公司 一种索非布韦中间体的制备方法
MA46839A (fr) * 2016-11-18 2021-03-24 Neurovive Pharmaceutical Ab Promédicaments hépatiques d'ionophores de protons mitochondriaux
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
WO2019245444A1 (en) 2018-06-21 2019-12-26 Medivir Ab Base-modified cytidine nucleotides for leukemia therapy
JP7337539B2 (ja) * 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
WO2020171757A1 (en) * 2019-02-18 2020-08-27 Medivir Aktiebolag Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-pd1 or anti-pdl1 monoclonal antibody
CN110964057B (zh) * 2019-12-25 2022-05-06 东南大学 一种利用微流体反应装置制备索非布韦中间体的方法
CN113402546A (zh) * 2020-03-17 2021-09-17 浙江四维医药科技有限公司 一种瑞德西韦磷酸中间体尾链动态动力学拆分方法
JP7709456B2 (ja) * 2020-04-15 2025-07-16 メディヴィル・アクチエボラーグ 肝臓癌のためのｍｉｖ－８１８／レンバチニブ併用療法
CN113754692B (zh) * 2020-06-03 2022-06-10 上海交通大学 瑞德西韦中间体(s,s)-氨基磷酸酯的不对称催化合成方法
CN114685558A (zh) * 2020-12-28 2022-07-01 尚科生物医药（上海）有限公司 一种瑞德西韦中间体的制备方法
CN114249764A (zh) * 2021-11-10 2022-03-29 宁波大学 一种磷酰胺酯类前药的中间体及其制备方法与应用
WO2025155547A1 (en) * 2024-01-17 2025-07-24 University Of Georgia Research Foundation, Inc. An efficient synthesis of beta-l-5-[(e)-2-bromovinyl)-1-((2s,4s)-2-(hydroxymethyl)-1,3-(dioxolane-4-yl) uracil)] (l-bhdu) via chiral pure l-dioxolane

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
KR20030096226A (ko) * 2000-10-13 2003-12-24 샤이어 바이오켐 인코포레이티드 개선된 세포간 전달을 보이는 디옥소란 동족체
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2007106450A2 (en) * 2006-03-10 2007-09-20 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy
KR20090057050A (ko) * 2006-09-01 2009-06-03 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 암치료를 위한 트록사시타빈 전구약물
PL216525B1 (pl) * 2006-10-17 2014-04-30 Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk 5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
CN105934438A (zh) * 2013-11-27 2016-09-07 艾登尼克斯药业有限公司 用于治疗肝癌的核苷酸
KR102398714B1 (ko) * 2014-08-25 2022-05-17 메디비르 아베 암 치료를 위한 우리딘의 디옥솔란 유사체

Also Published As

Publication number Publication date
NZ762628A (en) 2023-04-28
IL250344B (en) 2020-01-30
AU2018201980A1 (en) 2018-04-12
AU2018201980B2 (en) 2019-05-16
KR20170046736A (ko) 2017-05-02
CA2956251C (en) 2022-10-25
IL266766B (en) 2020-05-31
EA201790328A1 (ru) 2017-08-31
HUE059640T2 (hu) 2022-12-28
US20230382931A1 (en) 2023-11-30
US10822360B2 (en) 2020-11-03
MX369649B (es) 2019-11-15
KR102396905B1 (ko) 2022-05-13
EA201890648A2 (ru) 2018-08-31
PT3572410T (pt) 2022-09-15
US20190389890A1 (en) 2019-12-26
US20200239502A1 (en) 2020-07-30
CN110804072A (zh) 2020-02-18
EP3186244B1 (en) 2020-04-22
CY1122945T1 (el) 2021-10-29
IL250344A0 (en) 2017-03-30
ES2927212T3 (es) 2022-11-03
US11447511B2 (en) 2022-09-20
IL266766A (en) 2019-07-31
JP2020090535A (ja) 2020-06-11
US10336780B2 (en) 2019-07-02
JP6905609B2 (ja) 2021-07-21
SG10201911558UA (en) 2020-01-30
DK3572410T3 (da) 2022-08-29
CN111269264A (zh) 2020-06-12
ZA201802864B (en) 2019-07-31
US20230117570A1 (en) 2023-04-20
HRP20201023T1 (hr) 2020-10-16
US10144750B2 (en) 2018-12-04
WO2016030335A1 (en) 2016-03-03
PT3186244T (pt) 2020-05-29
EP3186244A1 (en) 2017-07-05
SG10202001117YA (en) 2020-04-29
MY198325A (en) 2023-08-24
EA033300B1 (ru) 2019-09-30
ES2796089T3 (es) 2020-11-25
US20210054008A1 (en) 2021-02-25
BR112017003898B1 (pt) 2022-10-18
DK3186244T3 (da) 2020-07-13
CN110790789B (zh) 2023-05-12
CN107074826B (zh) 2020-05-22
AU2015308988B2 (en) 2018-04-26
KR102398714B1 (ko) 2022-05-17
PL3186244T3 (pl) 2020-11-16
PL3572410T3 (pl) 2022-10-03
KR20200035482A (ko) 2020-04-03
EA201890648A3 (ru) 2019-02-28
AU2015308988C1 (en) 2018-09-06
EP3572410B1 (en) 2022-07-20
CA3128645C (en) 2023-06-27
BR112017003898A2 (pt) 2017-12-05
EP3572410A1 (en) 2019-11-27
JP2017526677A (ja) 2017-09-14
JP6663424B2 (ja) 2020-03-11
PH12019501919A1 (en) 2020-09-14
EA031106B1 (ru) 2018-11-30
SG11201701172SA (en) 2017-03-30
CN110790789A (zh) 2020-02-14
CN110804072B (zh) 2023-05-12
US20190100541A1 (en) 2019-04-04
PH12017500184B1 (en) 2017-06-28
US20170267705A1 (en) 2017-09-21
PH12017500184A1 (en) 2017-06-28
HUE050705T2 (hu) 2020-12-28
CA2956251A1 (en) 2016-03-03
US10654877B2 (en) 2020-05-19
CN107074826A (zh) 2017-08-18
CA3128645A1 (en) 2016-03-03
NZ729118A (en) 2022-02-25
AU2015308988A1 (en) 2017-02-23
MX2017002328A (es) 2017-05-22

Similar Documents

Publication Publication Date Title
PH12019501919A1 (en) Dioxolane analogues of uridine for the treatment of cancer
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
IL254720A0 (en) Indoleamine 3,2-dioxygenase inhibitors for cancer treatment
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
SG10201908028SA (en) Cyclopropylamines as lsd1 inhibitors
ZA202000148B (en) Heterocyclic inhibitors of atr kinase
MX2016015862A (es) Compuestos inhibidores de la cinasa de union a tank.
TN2019000211A1 (en) Antitumoral compounds
CR20200362A (es) CICLOPROPILAMINA COMO INHIBIDORES DE LA LSD1 (Divisional 2016-0395)
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
MX2016012829A (es) Inhibidores de biaril cinasa.
MX2017003930A (es) Derivados de aminotriazina utiles como compuestos inhibidores de la cinasa de union a tank.
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
MX2017004037A (es) Derivados de acido boronico.
MX2017004043A (es) Derivados de acido boronico.
MX2017004046A (es) Derivados de acido boronico.
MX2016002924A (es) Inhibidores de cinasa a base de eter arilico.
MX2016009355A (es) Inhibidores de aril lactama cinasa.
AU2015295120A8 (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
GEP201706795B (en) Hexahydrofuropyrroles as pde1 inhibitors
EP3549582A3 (en) Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
PH12017500492A1 (en) Crystalline bace inhibitors
WO2014180882A3 (en) Treatment of brain metastasis from cancer
PH12017501063A1 (en) Compounds for the treatment of cancer